


R⁷ is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, carbonyl, or sulfonyl;

R⁸ is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, carbonyl, or sulfonyl; and

R⁹ is hydrogen, halo, cyano, alkyl, alkenyl, alkoxy, aminoalkyl, heteroalkyl, cycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, heterocyclyl, amino, amido, carbonyl, thiol, sulfinyl, or sulfonyl;


provided that a compound of formula (I) is not:



[0012b] In a second aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound of the first aspect or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient, diluent, or carrier.

~~**[0012c]** In a third aspect of the present disclosure, there is provided a use of a compound of the first aspect, or a pharmaceutically acceptable salt or stereoisomer thereof, for the manufacture of a medicament for the treatment, prevention or management of a CNS or metabolic disorder, wherein a therapeutically or prophylactically effective amount of said medicament is to be administered to a subject.~~

[0013] Provided herein are compounds of formula (I), or pharmaceutically acceptable salts or stereoisomers thereof:




(I),

wherein X, Y, Z, R, B, m, and n are defined herein elsewhere. The compounds are useful for treating various diseases or disorders, such as CNS disorders and metabolic disorders.

[0014] Also provided herein are compositions and dosage forms comprising, a compound

31. The compound of claim 32, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

32. A pharmaceutical composition comprising a compound of any one of claims 1 to 31 or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient, diluent, or carrier.

33. The pharmaceutical composition of claim 32, which further comprises one or more additional active agents.

~~34. Use of a compound of any one of claims 1 to 31, or a pharmaceutically acceptable salt or stereoisomer thereof, for the manufacture of a medicament for the treatment, prevention or management of a CNS or metabolic disorder, wherein a therapeutically or prophylactically effective amount of said medicament is to be administered to a subject.~~

~~35. The use of claim 34, wherein the disorder is a neurological disorder, schizophrenia, schizophrenia-related disorder, schizophrenia spectrum disorder, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, schizoaffective disorder, schizophreniform disorder, paraphrenia, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, delusional disorder, psychosis, disease having a psychosis component, psychotic disorder, brief psychotic disorder, Alzheimer's psychosis, Parkinson's psychosis, shared psychotic disorder, substance-induced psychotic disorder, psychotic disorder due to a general medical condition, psychoaffective disorder, aggression, delirium, excitative psychosis, Tourette's syndrome, mania disorder, organic psychosis, NOS psychosis, convulsion, seizure, agitation, posttraumatic stress disorder, behavior disorder, neurodegenerative disease, Huntington's disease, Alzheimer's disease, Parkinson's disease, dyskinesia, dementia,~~

mood disorder, bipolar disorder, anxiety, depression, major depressive disorder, unipolar depression, treatment resistant depression, dysthymia, affective disorder, seasonal affective disorder, obsessive-compulsive disorder, attention deficit disorder, attention deficit hyperactivity disorder, vertigo, pain, neuropathic pain, sensitization accompanying neuropathic pain, inflammatory pain, fibromyalgia, migraine, cognitive impairment, cognitive impairment associated with schizophrenia, cognitive deficit in Alzheimer's disease, cognitive deficit in Parkinson's disease, movement disorder, restless leg syndrome, multiple sclerosis, sleep disorder, substance abuse or dependency, addiction, eating disorder, autism, obesity, undesirable weight retention or weight gain, metabolic syndrome, diabetes, non-insulin dependent diabetes, impaired glucose tolerance, or hyperglycemia.

36. The use of claim 34, wherein the disorder is schizophrenia, cognitive impairment associated with schizophrenia, cognitive impairment, psychosis, depression, or Huntington's disease.

37. The use of any one of claims 34 to 36, wherein a second active agent is to be further administered to said subject.